Last reviewed · How we verify
SGLT-2 inhibitor
SGLT-2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.
SGLT-2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes, Chronic kidney disease.
At a glance
| Generic name | SGLT-2 inhibitor |
|---|---|
| Also known as | Empagliflozin, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, empagliflozin (Jardiance®), dapagliflozin (Farxiga®), canagliflozin (Invokana®) |
| Sponsor | Peking University People's Hospital |
| Drug class | SGLT-2 inhibitor |
| Target | SGLT-2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT-2 inhibitors work by inhibiting the SGLT-2 transporter protein located in the proximal tubule of the nephron. This prevents the reabsorption of filtered glucose back into the bloodstream, causing glucose to be excreted in the urine. This mechanism lowers blood glucose levels in a glucose-dependent manner and provides additional cardiovascular and renal protective benefits.
Approved indications
- Type 2 diabetes mellitus
- Cardiovascular risk reduction in patients with type 2 diabetes
- Chronic kidney disease
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Diabetic ketoacidosis
- Volume depletion
Key clinical trials
- Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction (PHASE3)
- Sodium-Glucose Cotransporter 2 Inhibitor Use in a National Heart Failure Telemonitoring Program
- Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. (NA)
- Surgical or Medical Treatment (PHASE4)
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (PHASE3)
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure (PHASE4)
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGLT-2 inhibitor CI brief — competitive landscape report
- SGLT-2 inhibitor updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI